Offer Amir1, Tuvia Ben-Gal2, Jean Marc Weinstein3, Jorge Schliamser4, Daniel Burkhoff5, Aharon Abbo6, William T Abraham7. 1. Cardio-Vascular Institute, Baruch Padeh Medical Center, Poriya, Israel; Faculty of Medicine in the Galilee, Bar Ilan University, Tiberias, Israel. 2. Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel. 3. Cardiology Department, Soroka Medical Center, Beer-Sheva, Israel. 4. Lady Davis Carmel Medical Center, Haifa, Israel. 5. Columbia University, New York, NY, United States. 6. Sensible Medical Innovations Ltd., Netanya, Israel. 7. Division of Cardiovascular Medicine, The Ohio State University, OH, USA. Electronic address: William.Abraham@osumc.edu.
Abstract
OBJECTIVE: We tested whether remote dielectric sensing (ReDS)-directed fluid management reduces readmissions in patients recently hospitalized for heart failure (HF). BACKGROUND: Pulmonary congestion is the most common cause of worsening HF leading to hospitalization. Accurate remote monitoring of lung fluid volume may guide optimal treatment and prevent re-hospitalization. ReDS technology is a quantitative non-invasive method for measuring absolute lung fluid volume. METHODS: Patients hospitalized for acute decompensated HF were enrolled during their index admission and followed at home for 90days post-discharge. Daily ReDS readings were obtained using a wearable vest, and were used as a guide to optimizing HF therapy, with a goal of maintaining normal lung fluid content. Comparisons of the number of HF hospitalizations during ReDS-guided HF therapy were made, both to the 90days prior to enrollment and to the 90days following discontinuation of ReDS monitoring. RESULTS: Fifty patients were enrolled, discharged, and followed at home for 76.9±26.2days. Patients were 73.8±10.3years old, 40% had LVEF above 40%, and 38% were women. Compared to the pre- and post-ReDS periods, there were 87% and 79% reductions in the rate of HF hospitalizations, respectively, during ReDS-guided HF therapy. The hazard ratio between the ReDS and the pre-ReDS period was 0.07 (95% CI [0.01-0.54] p=0.01), and between the ReDS and the post-ReDS period was 0.11 (95% CI [0.014-0.88] p=0.037). CONCLUSIONS: These findings suggest that ReDS-guided management has the potential to reduce HF readmissions in acute decompensated HF patients recently discharged from the hospital.
OBJECTIVE: We tested whether remote dielectric sensing (ReDS)-directed fluid management reduces readmissions in patients recently hospitalized for heart failure (HF). BACKGROUND: Pulmonary congestion is the most common cause of worsening HF leading to hospitalization. Accurate remote monitoring of lung fluid volume may guide optimal treatment and prevent re-hospitalization. ReDS technology is a quantitative non-invasive method for measuring absolute lung fluid volume. METHODS:Patients hospitalized for acute decompensated HF were enrolled during their index admission and followed at home for 90days post-discharge. Daily ReDS readings were obtained using a wearable vest, and were used as a guide to optimizing HF therapy, with a goal of maintaining normal lung fluid content. Comparisons of the number of HF hospitalizations during ReDS-guided HF therapy were made, both to the 90days prior to enrollment and to the 90days following discontinuation of ReDS monitoring. RESULTS: Fifty patients were enrolled, discharged, and followed at home for 76.9±26.2days. Patients were 73.8±10.3years old, 40% had LVEF above 40%, and 38% were women. Compared to the pre- and post-ReDS periods, there were 87% and 79% reductions in the rate of HF hospitalizations, respectively, during ReDS-guided HF therapy. The hazard ratio between the ReDS and the pre-ReDS period was 0.07 (95% CI [0.01-0.54] p=0.01), and between the ReDS and the post-ReDS period was 0.11 (95% CI [0.014-0.88] p=0.037). CONCLUSIONS: These findings suggest that ReDS-guided management has the potential to reduce HF readmissions in acute decompensated HF patients recently discharged from the hospital.
Authors: Varol Burak Aydemir; Supriya Nagesh; Md Mobashir Hasan Shandhi; Joanna Fan; Liviu Klein; Mozziyar Etemadi; James Alex Heller; Omer T Inan; James M Rehg Journal: IEEE Trans Biomed Eng Date: 2019-08-15 Impact factor: 4.538
Authors: Eva M Boorsma; Jozine M Ter Maaten; Kevin Damman; Wilfried Dinh; Finn Gustafsson; Steven Goldsmith; Daniel Burkhoff; Faiez Zannad; James E Udelson; Adriaan A Voors Journal: Nat Rev Cardiol Date: 2020-05-15 Impact factor: 32.419
Authors: Jessica H Huston; Robinson Ferre; Peter S Pang; Ovidiu Chioncel; Javed Butler; Sean Collins Journal: Am J Ther Date: 2018 Jul/Aug Impact factor: 2.688
Authors: Pierpaolo Pellicori; Elke Platz; Jeroen Dauw; Jozine M Ter Maaten; Pieter Martens; Emanuele Pivetta; John G F Cleland; John J V McMurray; Wilfried Mullens; Scott D Solomon; Faiez Zannad; Luna Gargani; Nicolas Girerd Journal: Eur J Heart Fail Date: 2020-11-23 Impact factor: 15.534
Authors: A Faragli; D Abawi; C Quinn; M Cvetkovic; T Schlabs; E Tahirovic; H-D Düngen; B Pieske; S Kelle; F Edelmann; Alessio Alogna Journal: Heart Fail Rev Date: 2021-09 Impact factor: 4.214